Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.711
Abstract: Teriflunomide, a disease‐modifying treatment approved for multiple sclerosis (MS), inhibits reversibly dihydroorotate dehydrogenase, an enzyme involved in de novo pyrimidine biosynthesis and down‐regulates proliferation of activated lymphocytes. We aimed to study the impact of this… read more here.
Keywords: blood immune; tolerogenic bias; induces tolerogenic; immune cells ... See more keywords